ArticleJournal of veterinary internal medicine2022
Evaluation of symmetric dimethylarginine in cats with acute kidney injury and chronic kidney disease.
Article in Journal of veterinary internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Beyond traditional biomarkers: do serum cystatin C and urinary cystatin B improve diagnostic precision in feline and canine renal disease? A systematic review and meta-analysis.Frontiers in veterinary science · 2026Pooled it
- Short-term mortality prediction based on biochemical blood markers in azotemic cattle with renal disease.Journal of veterinary internal medicine · 2026Article
- Understanding the Progression of Chronic Kidney Disease in Cats: From Pathophysiology to Emerging Biomarkers.Veterinary sciences · 2026Review
- Changes in serum symmetric dimethylarginine concentrations after treatment of feline hyperthyroidism with antithyroid medications.Journal of feline medicine and surgery · 2026Article
- Analytical and Quality Control Validation of a Novel Symmetric Dimethylarginine Assay in Dogs and Cats.Veterinary clinical pathology · 2025Article
- Renal Biomarkers in Companion Animals-A Review.Animals : an open access journal from MDPI · 2025Review
- Ultrasonographic measurement of renal length and cortical thickness in clinically healthy Korean raccoon dogs.Frontiers in veterinary science · 2025Article
- Symmetric dimethylarginine correlates with the urea, creatinine, potassium, and clinical scores in feline urethral obstructions.Journal of veterinary science · 2024Article
- Evaluation of symmetric dimethylarginine in cats with acute kidney injury and chronic kidney disease.Journal of veterinary internal medicine · 2022Article
- Shoulder arthrodesis as a treatment for severe shoulder deformity secondary to septic arthritis in two cats.JFMS open reportsArticle
- Association of Serum Symmetric Dimethylarginine Concentrations and Inflammation in Cats.Journal of veterinary internal medicineArticle
- Efficacy of Urine Asymmetric Dimethylarginine Concentration to Predict Azotemia in Hyperthyroid Cats After Radio-Iodine Treatment.Journal of veterinary internal medicineArticle
- Effect of storage temperature and time on measurement of serum symmetric dimethylarginine concentration using point-of-care and commercial laboratory analyzers in cats and dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 3 countries.
Funding
Abstract
backgroundSerum symmetric dimethylarginine (SDMA) concentrations are considered a biomarker for renal dysfunction in dogs and humans with acute kidney injury (AKI). No studies have assessed SDMA in cats with AKI. HYPOTHESIS/
objectivesSDMA correctly identifies cats with azotemic AKI. ANIMALS: Fifteen control cats, 22 with novel AKI, 13 with acute on chronic-AKI (AoC) and 19 with chronic kidney disease (CKD).
methodsRetrospective study. Cats with azotemia (serum creatinine concentrations >1.7 mg/dL) were defined as having AKI or CKD based on history, clinical signs, clinicopathological findings and diagnostic imaging, and classified using the International Renal Interest Society (IRIS) grading/staging systems. Serum SDMA concentrations were compared between groups with nonparametric methods, and correlations assessed using Spearman's correlation coefficient. Data are presented as median [range].
resultsSDMA concentrations were 11 (8-21) μg/dL, 36 (9-170)μg/dL, 33 (22-75) μg/dL and 25 (12-69) μg/dL in control, novel AKI, AoC and CKD cats. SDMA concentrations were significantly higher in cats with novel AKI (P < .001), AoC (P < .001) and CKD (P < .01) compared to controls. SDMA concentrations were significantly higher in cats with more advanced AKI (IRIS grade IV-V) compared to less severe AKI (IRIS grade II). Serum creatinine and SDMA concentrations had a significant correlation in cats with novel AKI (r CONCLUSIONS AND CLINICAL IMPORTANCE: Serum SDMA concentrations are elevated in cats with established AKI (novel and AoC) and CKD, providing evidence for use of SDMA as a biomarker for AKI in cats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.